(52) reported that tivantinib regulated BCRP upstream of exon 1α in HCC HepG2 cells and suggested that tivantinib could be administrated in combination therapy with 5-FU as hepatic arterial infusion chemotherapy (HAIC) and sorafenib against HCC. Here, ABCG2 is linked to hepatocellular carcinoma.